Real-world rates and sites of recurrence after neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer
Neoadjuvant chemoimmunotherapy (NAC + P) improves pathologic complete response (pCR) and survival in early-stage triple-negative breast cancer (TNBC) compared to neoadjuvant chemotherapy (NAC) alone. Real-world recurrence outcomes outside the trial setting remain unclear. This single-institution analysis compared two cohorts of patients with early-stage TNBC treated between July 2009 and April 2023: NAC + P ( n = 344) and NAC ( n = 513). Primary outcomes were local (LR), regional (RR), and distant recurrence (DR); secondary outcomes were DR sites and disease-free survival (DFS). The NAC + P cohort presented with less advanced disease at diagnosis. Overall pCR was higher in NAC + P (58% vs. 36%, p < 0.001). Two-year LR and RR rates did not differ. The 2-year DR rate was nearly halved in NAC + P (9.6% vs. 18%, p < 0.001) and remained lower among patients with residual disease (16% vs. 25%). Two-year brain recurrence was also lower (3.5% vs. 6.6%, p = 0.046). Overall pCR was independently associated with improved DFS in both cohorts, as were immune-related adverse events (irAEs) in NAC + P. In this real-world setting, NAC + P was associated with substantially lower 2-year DR, though the central nervous system remained a common site of recurrence. Beyond pathologic response, the development of irAEs may offer a treatment-specific marker of benefit.
Authors
- Nour K. Abuhadra (ORCID: https://orcid.org/0000-0003-2704-3855)
- Giacomo Montagna (ORCID: https://orcid.org/0000-0003-3511-369X)
- Rachel Han (ORCID: https://orcid.org/0000-0002-5999-3997)
- Lauren M. Perry (ORCID: https://orcid.org/0000-0002-1306-9950)
- Marisa Lazarus
- Lior Zvi Braunstein (ORCID: https://orcid.org/0000-0002-5127-0217)
- Stephanie Downs‐Canner (ORCID: https://orcid.org/0000-0002-6870-3285)
- Varadan Sevilimedu (ORCID: https://orcid.org/0000-0002-0938-9396)
- Nicholas Mai (ORCID: https://orcid.org/0000-0002-1900-7945)
- Hannah Yong Wen (ORCID: https://orcid.org/0000-0001-6794-5234)
- Monica Morrow (ORCID: https://orcid.org/0000-0003-4636-8313)
- George Plitas (ORCID: https://orcid.org/0000-0002-8357-9534)
- Ellen Yang (ORCID: https://orcid.org/0009-0008-9557-5988)
- Hanna Kissane
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41523-026-01070-4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute